Press Releases 60 Degrees Pharmaceuticals, Inc.

Equities

SXTP

US83006G1040

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-20 pm EDT			5-day change	1st Jan Change
0.275 ^USD	+2.80%		-2.41%	-73.04%

May. 30	60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients	CI
May. 20	60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis	Jun. 11	AQ
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind	May. 30	AQ
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	May. 20	AQ
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results	May. 15	AQ
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases	May. 08	AQ
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required	May. 02	AQ
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis	Apr. 03	AQ
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024	Mar. 14	AQ
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris	Feb. 20	AQ
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer	Feb. 08	AQ
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering	Jan. 31	PR
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering	Jan. 31	AQ
WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering	Jan. 30	PR
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering	Jan. 30	AQ
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting	Jan. 22	AQ
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements	Jan. 16	AQ
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024	Dec. 26	AQ
Thinking about buying stock in Sportsmap Tech Acquisition, Dune Acquisition, Macy's, Cybin, or 60 Degrees Pharmaceuticals?	Dec. 21	PR
60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease	Nov. 15	AQ
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston	23-10-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases 60 Degrees Pharmaceuticals, Inc.

Equities

SXTP

US83006G1040

Press Releases

Filters